On the public citation graph

Current and Future Options for Cytomegalovirus Reactivation in Hematopoietic Cell Transplantation Patients

https://doi.org/10.2217/fmb-2017-0095

0 signed · 32 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.bbmt.2016.01.009openalex-snapshot

Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial

inferredcites →https://doi.org/10.1016/j.hoc.2010.11.011openalex-snapshot

Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients

inferredcites →https://doi.org/10.1016/j.jcv.2014.11.033openalex-snapshot

Cytomegalovirus infection in the Netherlands: Seroprevalence, risk factors, and implications

inferredcites →https://doi.org/10.1016/j.jcyt.2014.02.010openalex-snapshot

The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches

inferredcites →https://doi.org/10.1016/s1473-3099(11)70024-xopenalex-snapshot

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

inferredcites →https://doi.org/10.1016/s2352-3026(15)00289-6openalex-snapshot

Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

inferredcites →https://doi.org/10.1056/nejmoa1303688openalex-snapshot

CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation

inferredcites →https://doi.org/10.1056/nejmoa1309533openalex-snapshot

Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation

inferredcites →https://doi.org/10.1111/bjh.12363openalex-snapshot

Management of cytomegalovirus infection in haemopoietic stem cell transplantation

inferredcites →https://doi.org/10.1111/j.1399-3062.2011.00706.xopenalex-snapshot

A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low‐, intermediate‐, and high‐risk groups: reactivation risk is increased by graft‐versus‐host disease only in the intermediate‐risk group

inferredcites →https://doi.org/10.1182/blood-2003-10-3616openalex-snapshot

The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy

inferredcites →https://doi.org/10.1182/blood-2007-11-121558openalex-snapshot

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

inferredcites →https://doi.org/10.2807/ese.16.25.19896-enopenalex-snapshot

Seroprevalence to cytomegalovirus in the Portuguese population, 2002-2003

inferredcites →https://doi.org/10.4084/mjhid.2016.031openalex-snapshot

CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4005580openalex-extracted

The Establishment of a CMV-Specific CD8 + T-Cell Threshold by Kinetic Modelling for Prediction of Post-HSCT Reactivation

inferred← citeshttps://doi.org/10.1002/jmv.70489openalex-snapshot

Epstein–Barr Virus Infection and CD4+CD28+ T Cells Immune Construction Status Were Associated With the Incidence of Cytomegalovirus Encephalitis in Patients After Hematopoietic Stem Cell Transplantation

inferred← citeshttps://doi.org/10.1002/jmv.70905openalex-snapshot

Sensitive and Rapid Dual One‐Tube Recombinase Aided PCR Assays for the Simultaneous Detection of Cytomegalovirus, Epstein‐Barr Virus, Human Herpesvirus 6, and Herpes Simplex Virus 1/2 in Whole Blood From Children Undergoing Hematopoietic Stem Cell Transplantation

inferred← citeshttps://doi.org/10.1007/978-3-030-57317-1_4openalex-snapshot

Antiviral Prophylaxis

inferred← citeshttps://doi.org/10.1016/j.isci.2022.105340openalex-snapshot

The establishment of a cytomegalovirus -specific CD8+ T-cell threshold by kinetic modeling for the prediction of post-hemopoietic stem cell transplant reactivation

inferred← citeshttps://doi.org/10.1016/j.jiac.2022.05.020openalex-snapshot

Intra-host diversity of drug-resistant cytomegalovirus: A case report of cytomegalovirus infection after allogeneic hematopoietic cell transplantation

inferred← citeshttps://doi.org/10.1093/jac/dkab195openalex-snapshot

Ganciclovir therapeutic drug monitoring in transplant recipients

inferred← citeshttps://doi.org/10.1111/petr.13882openalex-snapshot

Use of low cell dose for unmanipulated donor lymphocyte for management of cytomegalovirus infection: A single‐center experience

inferred← citeshttps://doi.org/10.1128/jvi.00880-18openalex-snapshot

Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase

inferred← citeshttps://doi.org/10.2217/fmb-2018-0250openalex-snapshot

Letermovir for Prophylaxis of Cytomegalovirus Manifestations in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients

inferred← citeshttps://doi.org/10.3389/fmicb.2024.1405652openalex-snapshot

Reactivation of cytomegalovirus and bloodstream infection and its impact on early survival after allogeneic haematopoietic stem cell transplantation: a multicentre retrospective study

inferred← citeshttps://doi.org/10.3389/fonc.2021.740079openalex-snapshot

Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience

inferred← citeshttps://doi.org/10.3390/ijms20112666openalex-snapshot

Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy

inferred← citeshttps://doi.org/10.3390/ijms21103663openalex-snapshot

Delayed NK Cell Reconstitution and Reduced NK Activity Increased the Risks of CMV Disease in Allogeneic-Hematopoietic Stem Cell Transplantation

inferred← citeshttps://doi.org/10.3390/pathogens9110869openalex-snapshot

Regulation of the MIE Locus During HCMV Latency and Reactivation

inferred← citeshttps://doi.org/10.4166/kjg.2023.139openalex-snapshot

Infectious Gastric Diseases Other than Helicobacter

inferred← citeshttps://doi.org/10.7704/kjhugr.2019.0018openalex-snapshot

Gastric Ulcers with Cytomegalovirus Infection in an Immunocompetent Patient

inferred← citeshttps://doi.org/10.7704/kjhugr.2024.0027openalex-snapshot

Viral Infection in Upper Gastrointestinal Tract

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.